Trumping TRIPS: Indian Patent Proficiency and the Evolution of an Evergreening Enigma

Oxford University Commonwealth Law Journal, 18:1, 16-45, DOI: 10.1080/14729342.2018.1455479

30 Pages Posted: 30 Jul 2018

See all articles by Shamnad Basheer

Shamnad Basheer

Nirma University - Institute of Law

Date Written: April 11, 2018

Abstract

Section 3(d) of India’s Patents Act forbids patents on pharmaceutical substances that do not demonstrate a significantly enhanced efficacy over and above prior known substances. This article discusses the long and tortuous history of the provision. Only after an extended period of difficulty did India get to grips with World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and interpret it strategically to benefit the nation and its industry. This sophistication reached a near crescendo with the emergence of section 3(d), its crude drafting notwithstanding. India’s efforts to tailor its patent regime to promote the national interest whilst remaining compliant with TRIPS stands in stark contrast to a number of other countries that have simply toed the line of the developed world’s maximalist intellectual property (IP) agenda. As such, it represents a significant milestone and a valuable lesson in the IP and development debates.

Suggested Citation

Basheer, Shamnad, Trumping TRIPS: Indian Patent Proficiency and the Evolution of an Evergreening Enigma (April 11, 2018). Oxford University Commonwealth Law Journal, 18:1, 16-45, DOI: 10.1080/14729342.2018.1455479. Available at SSRN: https://ssrn.com/abstract=3210370

Shamnad Basheer (Contact Author)

Nirma University - Institute of Law ( email )

Sarkhej-Gandhinagar Highway
Gota
Ahmedabad, Gujarat 382 481
India

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
207
Abstract Views
541
rank
154,341
PlumX Metrics